BioCentury
ARTICLE | Strategy

Servicing CV

miRagen deal: Servier banks on novel drugs to grow cardiovascular business

November 7, 2011 8:00 AM UTC

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs.

Last month, Servier agreed to pay $45 million up front to miRagen Therapeutics Inc. to develop and commercialize the biotech's preclinical micro-RNA-targeting agents for cardiovascular disease...